Market Place
Sourcing Support
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
06 Aug 2024 //
PR NEWSWIRE
Blueprint to pull Gavreto in certain markets
09 Jan 2024 //
ENDPTS
Genentech, Blueprint tout full approval for Gavreto in rare type of lung cancer
10 Aug 2023 //
ENDPTS
Roche`s Gavreto (pralsetinib) Receives Approval in Europe
12 Jul 2023 //
EMA
Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial
05 Jul 2023 //
FIERCE PHARMA
Genentech Withdraws US Indication for Pralsetinib in Advanced or Metastatic RET+
30 Jun 2023 //
ONCLIVE
After splashing $1B, Roche returns Gavreto to Blueprint
24 Feb 2023 //
FIERCE PHARMA
Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
12 Aug 2022 //
NEWSWIRE
Roche`s Biologic Gavreto (Pralsetinib) Receives Approval in Europe
24 Mar 2022 //
EMA
European Commission approves Roche’s Gavreto (pralsetinib)
19 Nov 2021 //
GLOBENEWSWIRE
Blueprint Medicines Reports Third Quarter 2021 Financial Results
28 Oct 2021 //
PRNEWSWIRE
Euro Roundup: CHMP recommends drugs from Biogen & Roche, knocks back Pfizer
23 Sep 2021 //
RAPS
Roche gets +ve CHMP opinion for Gavreto in RET fusion-positive advanced NSCLC
20 Sep 2021 //
PHARMABIZ
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for lung cancer
17 Sep 2021 //
GLOBENEWSWIRE
Eli Lilly blazes new trail for RET inhibitor, ginning up response 9 solid tumor
12 Apr 2021 //
ENDPTS
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib)
01 Dec 2020 //
BLUEPRINTMEDICINES
Genentech Announces FDA Approval of Gavreto (pralsetinib)
01 Dec 2020 //
BUSINESSWIRE
FDA Action Alert: Blueprint, Liquidia, Revance, Rhythm and Merck
23 Nov 2020 //
BIOSPACE
Catalent Signs Commercial Supply Agreement with Blueprint Medicines GAVRETO™
23 Nov 2020 //
PRESSRELEASE
Blueprint Announces Benefits Of GAVRETO In RET-Mutant Medullary Thyroid Cancer
20 Sep 2020 //
PRNEWSWIRE
PANTHERx Pharmacy Selected to Distribute GAVRETO (pralsetinib)
15 Sep 2020 //
BIOSPACE
Genetech scores sixth FDA approval in lung cancer with Gavreto
09 Sep 2020 //
PHARMAFILE
Roche announces FDA approval of Gavreto (pralsetinib)
08 Sep 2020 //
PRESS RELEASE
Genetech scores sixth FDA approval in lung cancer with Gavreto
07 Sep 2020 //
PHARMAFILE
Blueprint, Roche challenge Lilly with RET cancer drug Gavreto
05 Sep 2020 //
FIERCE PHARMA
Genentech Announces FDA Approval of Gavreto (pralsetinib)
04 Sep 2020 //
BUSINESSWIRE
Blueprint Announces Submission of New Drug Application to FDA for Pralsetinib
01 Jul 2020 //
BLUEPRINTMEDICINES
Blueprint Medicines Announces Submission of NDA to FDA for Pralsetinib
01 Jul 2020 //
PRNEWSWIRE
Blueprint Medicines Announces Data Presentations Highlighting Progress
13 May 2020 //
PRNEWSWIRE
Lilly looms over Blueprint as the biotech files targeted cancer drug
08 Jan 2020 //
BIOPHARMA DIVE
Lilly looms over Blueprint as the biotech files targeted cancer drug
08 Jan 2020 //
BIOPHARMA DIVE
Lilly looms over Blueprint as the biotech files targeted cancer drug
07 Jan 2020 //
BIOPHARMA DIVE
